Results 101 to 110 of about 2,412,458 (308)

Degradation mechanism of the von Willebrand factor A2 domain by nattokinase

FEBS Letters, EarlyView.
Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto, Masatomo So, Ayako Furukawa, Kenji Sugase   +3 more
wiley   +1 more source

Combination of Whole Body MRI and MY-RADS: A Promising Standardised Approach for Treatment Response Evaluation in Multiple Myeloma Patients [PDF]

Journal of Clinical and Diagnostic Research
Introduction: Multiple Myeloma (MM) is a malignancy that impacts the bones, kidneys, and immune system. Whole-body Magnetic Resonance Imaging (MRI) is recognised as the most sensitive modality for bone marrow assessment, providing advantages such as ...
Dipu Bhuyan, Hrishikesh Choudhury, Baloy Jyoti Talukdar, Subhosree Dey, Sushant Agarwal, Aditi Das, Rishabh   +6 more
doaj   +1 more source

Study on physio-chemical properties of plasma polymerization in C2H2/N2 plasma and their impact on COL X [PDF]

, 2017
Nitrogen-containing plasma polymerization is of considerable interest for tissue engineering due to their properties on cell adhesion and mesenchymal stem cells (MSCs) response.
Abdijahed, Sara, Ardeshirylajimi, Abdolreza, Farivar, Shirin, Ghafouri, Samaneh, Hosseini, Seyed Iman, Rezaei, Fatemeh, Shokri, Babak   +6 more
core   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Report of two rare cases of plasma cell granuloma of the gingiva [PDF]

Revista Portuguesa de Estomatologia, Medicina Dentária e Cirurgia Maxilofacial
Plasma cell granuloma is a rare benign, occasionally aggressive lesion with an unclear etiopathogenesis characterized by plasma cell infiltration. It occurs mainly in the lungs but can also affect the liver, kidneys, brain, and heart.
Hannah Gil de Farias Morais, Renata Roque Ribeiro, José Nazareno Moreira de Aguiar Júnior, Victor Diniz Borborema dos Santos, Hevio Freitas de Lucena, Roseana de Almeida Freitas   +5 more
doaj   +1 more source

Comparison of three radio-frequency discharge modes on the treatment of breast cancer cells in vitro [PDF]

, 2019
Non-thermal plasmas (NTPs) are known for their ability to induce thermal-free cytotoxic effects on cancer cells. However, as the variety of NTP devices increases, comparison of their cytotoxic effect becomes increasingly essential.
Boisvert, Jean-Sébastien, Coulombe, Sylvain, Glory, Audrey, Lafontaine, Julie, Wong, Philip   +4 more
core   +1 more source

Plasma cell leukaemia

Porto Biomedical Journal, 2016
Plasma cell leukaemia (PCL) is a rare and aggressive disease. Diagnosis is made when there are >2000/#mL circulating plasma cells in peripheral blood or plasmacytosis >20% of total leukocyte count. We report a case of a 51-year old man with generalized bone pain and constitutional symptoms.
Braga, Carlos Galvão, Rodrigues, Ana Raquel, Alves, Marina, Portela, Catarina, Pinto, Luísa, Marques, Herlander   +5 more
openaire   +2 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption. [PDF]

, 2018
Combination antiretroviral therapy controls but does not cure HIV-1 infection because a small fraction of cells harbor latent viruses that can produce rebound viremia when therapy is interrupted. The circulating latent virus reservoir has been documented
Barton, John, Caskey, Marina, Cohen, Yehuda Z, Cohn, Lillian B, Gruell, Henning, Jankovic, Mila, Klein, Florian, Lorenzi, Julio CC, Lu, Ching-Lan, Mendoza, Pilar, Nogueira, Lilian, Nussenzweig, Michel C, Oliveira, Thiago Y, Pai, Joy A   +13 more
core   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source